Compare BridgeBio Pharma Inc (BBIO) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Nvidia Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Nvidia Corp trades at $218.07 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 317.3× BridgeBio Pharma Inc's market cap, and Nvidia Corp pays a 0.46% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NVDA | |
|---|---|---|
Market Cap | $16.61B | $5.27T |
Sector | Health | Technology |
52-Week High | $90.17 | $235.75 |
52-Week Low | $47.29 | $165.17 |
Enterprise Value | $18.16B | $5.20T |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
NVIDIA (NVDA) trades at $217.48, down 2.89% on the day, with strong fundamentals including a 55.84% net income margin and 114.29% ROE. The stock shows a bullish technical trend, supported by moving averages, and has consistently beaten earnings expectations. Recent news highlights AI-driven growth potential, though some articles caution about valuation and market rotation.
Outlook remains positive with a consensus price target of $325.86, implying significant upside. Key opportunities include leadership in AI chips and robust financials, while risks involve high valuation multiples, competition, and macroeconomic sensitivity. The stock presents a growth opportunity tempered by execution and market risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
